Joseph Fanelli, MD
Psychiatry · Munster, INNPI 1205962495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $296,064 of the $443,114 with a category attached, or 66.8%. 20 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 43.6% of the total. 2025 is the largest year on record at $136,093, 5.1 times the $26,751 reported in 2019. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $853.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$193K
- Alkermes, Inc.$128K
- Otsuka America Pharmaceutical, Inc.$114K
- Indivior Inc.$3K
- Brainsway USA Inc$2K
- AbbVie$731
- plus $2K from 14 others
What the payments were for
- Consulting fees$119,65727%
- Speaking & faculty fees$296,06467%
- Travel & lodging$12,4793%
- Food & beverage$14,8243%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 123 | $193,175 |
| Alkermes, Inc. | 139 | $128,357 |
| Otsuka America Pharmaceutical, Inc. | 130 | $113,992 |
| Indivior Inc. | 9 | $2,859 |
| Brainsway USA Inc | 1 | $2,150 |
| AbbVie(2 entities) | 45 | $731 |
| Johnson & Johnson | 23 | $539 |
| Teva Pharmaceuticals USA, Inc. | 4 | $244 |
| Lundbeck LLC | 14 | $243 |
| Neurocrine Biosciences, Inc. | 7 | $209 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $99 |
| Corium, LLC | 1 | $78 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Acadia Pharmaceuticals Inc | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Shire North American Group Inc | 2 | $33 |
| Luye Pharma (USA) Ltd. | 1 | $30 |
| Harmony Biosciences LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$318,723
- LYBALVI$197,379
- Auvelity$191,908
- ABILIFY MAINTENA$112,221
- ABILIFY ASIMTUFII$70,108
- ARISTADA INITIO$68,059
- PERSERIS$2,750
- Brainsway Deep TMS$2,150
- REXULTI$1,298
- UZEDY$125
- CAPLYTA$125
- SPRAVATO$110
- INVEGA SUSTENNA$110
- INVEGA TRINZA$110
How this compares
$443,114 in reported general payments places this provider in the 95th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 46 | $164,234 |
| RexultiBrexpiprazole | 38 | $55,749 |
| AuvelityDextromethorphan Hbr/Bupropion | 49 | $50,649 |
| Modafinil | 23 | $22,093 |
| RybelsusSemaglutide | 20 | $21,384 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,678 |
| OzempicSemaglutide | 12 | $19,306 |
| VraylarCariprazine Hcl | 12 | $16,296 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 39 | $13,954 |
| Aripiprazole | 58 | $9,237 |
| Ramelteon | 58 | $9,207 |
| Lurasidone Hcl | 11 | $6,208 |
| Armodafinil | 51 | $5,759 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 41 | $5,306 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $4,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $539 | $164,23446 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $113,992 | $55,74938 claims |
| Axsome Therapeutics, Inc.Auvelity | $193,175 | $50,64949 claims |
| Alkermes, Inc.Lybalvi | $128,357 | $19,67812 claims |
| AbbVieVraylar | $731 | $16,29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Munster
- Sanker JayachandranMunster$22K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
- Charles BeasleyIndianapolis$129K
- Muhammad MunirAnderson$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.